click on circles to display study description...

Lou (FAVIPIRAVIR), 2020 ChiCTR2000029544

favipiravir (n=10) vs. standard of care (n=10)

randomized controlled trial

favipiravir
The first dose was 1600 mg or 2200mg orally, followed by 600 mg each time, three times a day, and the duration of administration was not more than 14 days

standard treatment
antiviral treatment included lopinavir/ritonavir (400 mg/100 mg, bid, po.) or darunavir/cobicistat (800 mg/150 mg, qd, po.) and arbidol (200 mg, tid, po.

3 arms: favipiravir (n=10), baloxavir marboxil (n=10), current antiviral treatment (n=10)

COVID 19 all comers

exclusion of considered as severe disease: has an ongoing respiratory deficiency and subjected to invasive mechanical ventilation; or presence of shock; or admitted to the ICU due to complications;

open-label, randomized

1 center, China

Time to clinical improvement was defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven category ordinal scale or live discharge from the hospital, whichever came first.

NCT04310228-FAVI (Zhao), 2020 ChiCTR2000030894

favipiravir (n=-9) vs. tocilizumab (n=-9)

randomized controlled trial

favipavir
Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day

tocilizumab
1 dose 4-8 mg/kg (max 400mg). 2nd dose within 24h if persistent fever

COVID 19 all comers

open label

10 centres, China

3 arms : Favipiravir Combined With Tocilizumab ; Favipiravir; Tocilizumab

Chang Chen et al., 2020 ChiCTR2000030254

favipiravir (n=120) vs. umifenovir (arbidol) (n=120)

randomized controlled trial

favipiravir
favipiravir tablets (1600 mg/time on the first day, twice a day; 600 mg/time from the second day to the end of the experiment, twice a day)

umifenovir
umifenovir (200 mg each time, 3 times a day, from the first day to the end of the trial)

COVID 19 all comers

double-blind

China, 3 hospitals

Clinical recovery was defined as continuous (>72 hours) recovery of body temperature, respiratory rate, oxygen saturation and cough relief after treatment

Some incorrectness in the paper (for example in the result table (table 2), it is not the rate ratio that is reported but the risk difference). Arise some concern about a selective reporting.

Andreas (NOR-Solidarity), 2021 NCT04321616

remdesivir (n=43) vs. standard of care (n=58)

randomized controlled trial

Remdesivir
Standard of care plus intravenous remdesivir 400 mg on day 1, then 200 mg daily up to 9 days.

Standard of care
Local SoC.

3 arms: remdesivir, hydroxychloroquine, standard of care. All study treatments were stopped at discharge. During the course of the study, local SoC changed as a result of the RECOVERY trial and updated WHO guidelines recommending systemic steroids for severe and critical COVID-19 (September 4th 2020).

COVID 19 all comers

adult patients (≥18 years), with confirmed SARS-2-CoV-2 infection by PCR, admitted to the hospital ward or the intensive care unit (ICU), with no anticipated transfer to a non-study hospital within 72 hours of inclusion. Informed consent by the study subject or legally authorized representative was provided prior to inclusion.

Open-label.

23 hospitals in Norway.

Norwegian NOR study (remdesivir), 2021 NCT04321616

remdesivir (n=43) vs. standard of care (n=58)

randomized controlled trial

Remdesivir
Standard of care plus 200 mg of intravenous remdesivir on day 1, then 100 mg daily up to 9 days. All study treatments were discontinued at discharge.

Standard care
Local SoC.

3 arms: hydroxychloroquine, remdesivir and standard of care. During the study, local SoC changed as the RECOVERY trial and updated WHO guidelines recommending systemic steroids for severe and critical COVID-19.

COVID 19 all comers

Adult patients (≥18 years) with SARS-CoV-2 infection confirmed by PCR who were admitted to the hospital ward or intensive care unit (ICU) with no anticipated transfer to a nonstudy hospital within 72 hours of inclusion. Informed consent by the study participant or legally authorized representative was provided before inclusion.

Open-label.

23 hospitals in Norway.

From 8 June 2020 on, NOR-Solidarity allocated patients only to SoC and remdesivir (hydroxychloroquine removed because of lack of evidence of its effectiveness).

Add-on Solidarity trial.

ELACOI (Standard of care), 2020 NCT04252885

umifenovir (arbidol) (n=16) vs. standard of care (n=7)

randomized controlled trial

arbidol
arbidol (100mg) (oral, 200mg TID for 7-14 days)

standard care

3 arms : lopinavir/ritonavir; arbidol and standard care

COVID 19 all comers

open-label

China, single center